Sanofi picks up Principia Biopharma for $3.7 billion

French pharmaceutical group Sanofi said Monday it has finalised acquisition of US biotech firm Principia Biopharma for $3.7 billion.

The operation, first announced in August, was aimed at boosting Sanofi's research and development into auto-immune and allergic diseases.

Sanofi agreed to pay $100 per share in cash for Principia Biopharma, a company with which it has been cooperating since 2017.

That year, Sanofi secured an exclusive global licence to develop and market Principia Biopharma BTK'168 drug for treating multiple sclerosis and other central nervous system illnesses. 

"The Principia acquisition further strengthens our core areas of auto-immune and allergic diseases," Sanofi chief executive Paul Hudson was quoted Monday as saying.

Beyond diseases of the nervous system, Principia hopes to develop a entire portfolio of similar drugs that could target different organ systems in patients suffering from "immune-mediated" diseases, chief executive Martin Babler said last month.

Topics: Sanofi , Principia Biopharma , auto-immune , allergic diseases
COMMENT DISCLAIMER: Reader comments posted on this Web site are not in any way endorsed by Manila Standard. Comments are views by readers who exercise their right to free expression and they do not necessarily represent or reflect the position or viewpoint of While reserving this publication’s right to delete comments that are deemed offensive, indecent or inconsistent with Manila Standard editorial standards, Manila Standard may not be held liable for any false information posted by readers in this comments section.
AdvertisementSpeaker GMA